Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma SA (IPHA) is a clinical-stage biotechnology leader advancing immuno-oncology therapies through innovative antibody development. This page serves as the definitive source for official company announcements and curated news coverage.
Key updates include clinical trial milestones, regulatory developments, strategic collaborations, and scientific advancements. Investors and researchers will find timely information on NK cell engager therapeutics, partnership expansions with major biopharma entities, and progress across the company's oncology pipeline.
All content is sourced directly from verified corporate communications and reputable financial analysis. Bookmark this page for streamlined access to IPHA's latest developments in harnessing innate immunity for cancer treatment breakthroughs.
Innate Pharma, listed on Euronext Paris (IPH) and Nasdaq (IPHA), clarified that their molecule SAR443579/IPH6101 was incorrectly mentioned as having breakthrough designation in an abstract published for the European Hematology Association 2024 Congress. The correct status is that the molecule has received US FDA Fast Track Designation, as communicated in June 2023. This clarification aims to rectify the misinformation released on May 14, 2024, by Sanofi.
Innate Pharma announced that four of its drug candidate abstracts have been accepted for presentation at the EHA 2024 Congress in Madrid, from June 13-16, 2024. Two abstracts focus on SAR443579 (IPH6101), an anti-CD123 NK cell engager developed with Sanofi, being tested in a Phase 1/2 trial for blood cancers. The other two abstracts highlight IPH6501, aimed at treating relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma, also in Phase 1/2 trials. Chief Medical Officer Dr. Sonia Quaratino underscored the potential benefits of these NK cell engagers for patients with high unmet medical needs.
Innate Pharma (NASDAQ: IPHA) released its Q1 2024 business update, highlighting key developments in its clinical pipeline and financial performance. The company presented preclinical data for IPH45, an anti-Nectin-4 ADC, at AACR 2024 and advanced IPH6501, its second-generation ANKET®, into clinical development for NHL. Partner Sanofi progressed SAR443579/IPH6101 to Phase 2 in blood cancers. For Q1 2024, Innate reported revenues of €6.6 million, down from €26 million in Q1 2023. The company's cash position stood at €113.9 million as of March 31, 2024, excluding a pending €4 million milestone payment from Sanofi. Innate anticipates a cash runway until the end of 2025. Multiple presentations at ASCO 2024, including results from the TELLOMAK Phase 2 trial for lacutamab, are scheduled. The FDA lifted a partial clinical hold on lacutamab's IND in January 2024. A conference call to discuss these results will be held today.
Innate Pharma SA has scheduled a conference call and webcast on May 14, 2024, to discuss the business progress during the first quarter of 2024. Key executives will provide updates on the company's performance and future plans.